Skip to content

Rational surgical margin contributes to optimal prognosis in appropriate candidates undergoing re-hepatectomy for recurrent hepatocellular carcinoma: a multicentric analyses

Rational surgical margin contributes to optimal prognosis in appropriate candidates undergoing re-hepatectomy for recurrent hepatocellular carcinoma: a multicentric analyses

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124748
Enrollment
Unknown
Registered
2026-05-17
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

Wide margin:NA
Narrow margin:NA

Sponsors

The Tenth People’s Hospital of Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–75 years; 2. Recurrence after radical resection for primary hepatocellular carcinoma (HCC), underwent repeat hepatectomy with a pathological confirmation of HCC; 3. Medical records available to allow preoperative assessment of MVI risk using a nomogram model; 4. The width of the surgical margin was clearly documented in the pathological report; 5. Complete medical records were available (including baseline characteristics, operative records, and follow-up data).

Exclusion criteria

Exclusion criteria: 1. The first hepatectomy was non-radical resection. 2. Tumor recurrence was diagnosed within 1 year after primary surgery. 3. Recurrent tumors were multiple, with a diameter > 5 cm, or located adjacent to vital anatomical structures, resulting in surgical difficulty. 4. Extrahepatic metastasis and tumor thrombus in the main portal vein, hepatic vein, or bile duct were present in both primary and recurrent tumors. 5. Liver function was worse than Child-Pugh Class A before repeat hepatectomy. 6. Received systemic anti-tumor therapy prior to re-hepatectomy (e.g., TACE or other interventional therapy, targeted therapy, immunotherapy). 7. Complicated with other malignant tumors. 8. Missing key information in medical records (e.g., surgical margin width, MVI risk score, follow-up data).

Design outcomes

Primary

MeasureTime frame
Over Survival;Recurrence rate;

Countries

China

Contacts

Public ContactJun Li

Department of Hepatobiliary and Pancreatic Surgery, the Tenth People’s Hospital of Tongji University

lijunlancet@tongji.edu.cn+86 138 1765 4087

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026